Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

YOU WONT BELIEVE: 2 - What They Never Told You

How Should Law Schools Handle Protests at Student Events?

It may be too late for Stanford Law School, but it's not too late for other institutions of higher learning.

Reason

Separating the Juice From the Pulp At Stanford

How should SLS squeeze out students who violated the code of conduct?

Reason

Dean Martinez's Letter to Stanford Law School Alumni

Reason

From analysis to the latest developments in health,
read the most diverse news in one place.

David Lat on the Stanford Law School Disruption of Speech by Fifth Circuit Judge Kyle Duncan

David Lat's Original Jurisdiction newsletter has, as usual, excellent and detailed coverage. I started quoting but then realized that I couldn't excerpt it and still do the matter justice; and quoting the whole thing would be unfair to Lat as an author. I therefore very much encourage you to read…

Reason

Livingston laboratory equipment firm acquired

The deal will see C&M Scientific continue to operate from central Scotland

Insider UK

What’s next for Artemis I after 2nd scrub?

ORLANDO, Fla. — What went wrong with Artemis I was on the launch pad at Kennedy Space Center, so that’s where NASA has decided to try and fix it.

Orlando Sentinel

Lanarkshire cheer squad searching for sponsors to compete in Wold Championship showdown in Florida

SLS Cheer and Dance have qualified to compete in Orlando next year

Daily Record

Read news from The Economist, FT, and more,
with one subscription

Andhra Pradesh: Tobacco farming back in favour as farmers get record prices

Average price jumps by over ₹30 per kg; global shortfall in output boosts demand for Indian leaf

The Hindu

SELLAS Life Sciences's Galinpepimut/Opdivo Combo Shows Increased Survival In Mesothelioma Patients

SELLAS Life Sciences Group Inc (NASDAQ:SLS) announced updated data from a Phase 1 clinical trial of galinpepimut-S (GPS), combined with Bristol-Myers Squibb Co's (NYSE:BMY) nivolumab (Opdivo) in with malignant pleural mesothelioma (MPM). The trial included patients who were either refractory or relapsed after at least one line of the standard of care therapy. Data from…

Benzinga

Sellas' Ovarian Cancer Candidate Shows Clinical Benefit In Pretreated Patients

SELLAS Life Sciences Group Inc (NASDAQ:SLS) announced topline data from its Phase 1/2 trial of galinpepimut-S (GPS) in WT1(+) relapsed or refractory platinum-resistant advanced metastatic ovarian cancer. The trial evaluated SELLAS' peptide immunotherapeutic combined with Merck & Co Inc's (NYSE:MRK) Keytruda (pembrolizumab). Data from 15 patients enrolled in the study has been preliminarily analyzed. Final…

Benzinga

Derek Jeter Celebrity Invitational at Baha Mar contributes over $1M to Turn 2 foundation

Ken Griffey Jr., Tino Martinez, Jorge Posada, CC Sabathia, Paige Spiranac and Ryan Rustand were all on hand.

USA Today Sports Media Group

Saudi Arabia Hosts Exhibition of the Latest 3D Sensory Innovations

Riyadh will host the Saudi Light and Sound (SLS) Expo, scheduled for May 16-18, in the first event dedicated to professional 3D lighting and sound equipment. The event is launched as a platform that enables participants to see, hear, and experience the latest technologies and illuminating innovations in lighting, sound,…

Asharq Al-Awsat

RBC Capital Bumps Up Solaris Resources Price Target By 11%

RBC Capital analyst Alexander Jackson raised the price target on Solaris Resources Inc (TSX:SLS) (OTC:SLSSF) to C$20 from C$18 while maintaining the Outperform rating on the shares. Solaris' Warintza Project remains one of the analyst's favorite undeveloped copper projects, and the mineral resource update confirmed the meaningful scale and above-average grades at Central, which, in…

Benzinga

Artemis-1's next-generation rocket faces setback from pocket-sized valve

The Moon-bound rocket needs to pass a test before it can ever see the light of Moon-day.

Inverse

Get all your
news in one place.

100's of premium titles.
One news app.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.